Antiphospholipid Syndrome and Reversible Posterior Leukoencephalophaty Syndrome

Poggio, Monica Bandettini di; Murdaca, Giuseppe; Puppo, Francesco; Primavera, A.

doi:10.1016/j.semarthrit.2009.08.004

Cited by 7 publications

(4 citation statements)

References 6 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some dissimilarities with the prior studies were observed in our cases. Several reports have suggested an association between aPL and PRES, 15,24 but we found no statistical difference in aPL positivity between patients with and without PRES. Our patients with PRES were relatively older than earlier cases in which PRES developed in mostly adolescent or young adults <40 years.…”

Section: Discussioncontrasting

confidence: 97%

Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome

et al. 2013

Lupus

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is an uncommon neurologic condition associated with systemic lupus erythematosus (SLE). This study aimed to demonstrate the risk factors and clinical outcome of PRES in patients with SLE. Fifteen patients with SLE were diagnosed with PRES by characteristic clinical manifestations and magnetic resonance imaging (MRI) features from 2000 to 2012. Clinical profiles and outcomes were assessed for this study population. Additionally, 48 SLE patients with neurologic symptoms who underwent brain MRI were included for comparative analyses. The median age and duration of SLE in patients with PRES was 27 and 6.1 years, respectively. Comparison between patients with and without PRES revealed significant differences in the presentation of hypertension and seizure, lupus nephritis with renal insufficiency, treatment with high-dose steroid and cyclophosphamide, recent transfusion, and lupus activity measured by SLE disease activity index. Renal failure was the single independent factor with a high odds ratio of 129.250 by multivariate analysis. Of 15 patients, four experienced relapse and two died of sepsis during hospitalization. Our results suggest that lupus nephritis with renal dysfunction and other related clinical conditions can precede the occurrence of PRES in patients with SLE. It is important to perform early brain imaging for a timely diagnosis of PRES when clinically suspected.

show abstract

Section: Discussioncontrasting

confidence: 97%

Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome

et al. 2013

Lupus

View full text Add to dashboard Cite

show abstract

“…Our final case of SSc with secondary APS resulted in the rare PRES (also known as reversible posterior leukoencephalopathy syndrome (RPLS)). There have only been a small number of reported cases of PRES in association with primary and secondary APS, often in association with high titre ACL IgM, as was found in our case (40)(41)(42)(43). To our knowledge this is the first reported case of PRES occurring in the context of SSc and secondary APS.…”

Section: Discussionsupporting

confidence: 52%

Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders

Chatterjee

Pauling

2020

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…The recognition of the antiphospholipid syndrome (APS) is critical for the institution of appropriate therapy [1, 17], but it occurs in SLE patients with or without NP disease. Neurological symptoms are significant manifestations of APS, including the recently described reversible posterior leucoencephalopathy syndrome [18], and endothelial dysfunction is well documented in SLE and APS [19]. Computed tomography (CT) does not recognize the diffuse presentations that may be detected by brain magnetic resonance imaging in the brains of NPSLE patients [20, 21].…”

Section: Introductionmentioning

confidence: 99%

Neuropsychiatric Features of a Cohort of Patients with Systemic Lupus Erythematosus

et al. 2012

View full text Add to dashboard Cite

In order to establish if neuropsychiatric systemic lupus erythematosus (NPSLE) can be identified by any characteristic other than those used to diagnose the neuropsychiatric (NP) disease itself, we retrospectively reviewed 98 systemic lupus erythematosus (SLE) patients followed over a mean period of 10 years. NPSLE was identified in 22 patients. Stroke and generalized seizures were the most frequent NP manifestations. The NPSLE and non-NPSLE groups were similar with regard to demographic characteristics, ACR criteria, serum autoantibodies, and frequency of hypertension and hypercholesterolemia. Of note, compared to the non-NPSLE group, NPSLE was associated with a higher frequency of smoking (78 versus 26%), organ damage (73 versus 34%), and cumulative mortality rate (14 versus 7%). The series of patients was further analysed according to the presence of antiphospholipid syndrome (APS). Significantly, the interval between the onset of NP disease and SLE diagnosis was shorter in the APS− (0.3 ± 1 years) than in the APS+ (5 ± 7 years) groups. Recurrence and/or persistence of NP events were only documented in the APS− group. Overall cumulative mortality was highest in NPSLE and in APS+ patients with inadequate anticoagulation control, identifying an aspect that requires improved vigilance and the development of novel therapeutic modalities.

show abstract

Antiphospholipid Syndrome and Reversible Posterior Leukoencephalophaty Syndrome

Cited by 7 publications

References 6 publications

Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome

Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome

Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders

Neuropsychiatric Features of a Cohort of Patients with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About